[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-341156-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-341156-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","pharmacological-characterization-of-sdx-7320evexomostat-a-novel-methionine-aminopeptidase-type-2-inhibitor-with-anti-tumor-and-anti-metastatic-activity","Pharmacological Characterization of SDX-7320/Evexomostat - A Novel Methionine Aminopeptidase Type 2 Inhibitor with Anti-tumor and Anti-metastatic Activity","","Methionine aminopeptidase type 2 (METAP2) is a conserved metalloprotease driving protein biosynthesis by removing the N-terminal methionine residue. METAP2 inhibition is attractive for cancer therapy because METAP2 is overexpressed across human cancers and its substrates’ activity can change after inhibition, including the fumagillin-identified METAP2 target. SDX-7320 (evexomostat), a polymer–drug conjugate of the novel METAP2 inhibitor SDX-7539, is characterized through in vitro binding, enzyme, and cell assays. Polymer conjugation improves drug-like behavior, reduces CNS exposure, and prolongs half-life, supporting anti-tumor and anti-metastatic activity across multiple cancer models.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/pharmacological-characterization-of-sdx-7320evexomostat-a-novel-methionine-aminopeptidase-type-2-inhibitor-with-anti-tumor-and-anti-metastatic-activity/341156/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/pharmacological-characterization-of-sdx-7320evexomostat-a-novel-methionine-aminopeptidase-type-2-inhibitor-with-anti-tumor-and-anti-metastatic-activity/341156.png","ImageObject",300,407,{"name":42,"@type":43},"Eliana","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What biological role does METAP2 play that makes it relevant to cancer therapy?","Question",{"text":63,"@type":64},"METAP2 is a metalloprotease that removes the N-terminal methionine from nascent polypeptides. Its inhibition can alter post-translational modifications, protein folding, localization, and stabilization, contributing to anti-tumor effects.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Why are fumagillin-based METAP2 inhibitors of interest, and what limitations exist?",{"text":68,"@type":64},"Fumagillin irreversibly binds selectively to METAP2 and inactivates its aminopeptidase activity, leading to downstream anti-tumor and anti-metastatic effects. Prior derivatives such as TNP-470 showed dose-limiting neurological toxicity and other pharmacokinetic or solubility challenges.",{"name":70,"@type":61,"acceptedAnswer":71},"How does SDX-7320 (evexomostat) differ from earlier small-molecule approaches?",{"text":72,"@type":64},"SDX-7320 is a polymer–drug conjugate of the METAP2 inhibitor SDX-7539 designed to improve properties limited in earlier generations. The high molecular weight polymer conjugation reduces CNS exposure, prolongs half-life, and enables convenient administration.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},341156,1790141300,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},4398048949847,"https://ap-avatar.wpscdn.com/avatar/400002536579ef2da7f?_k=1778318612642679267","FIRST DISCLOSURE  \nPharmacological Characterization of SDX-7320/  \nEvexomostat: A Novel Methionine Aminopeptidase Type 2 Inhibitor with Anti-tumor and Anti-metastatic Activity  \nPeter Cornelius1, Benjamin A. Mayes1, John S. Petersen1, David J. Turnquist1, Pierre J. Dufour1, Andrew J. Dannenberg2, James M. Shanahan1, and Bradley J. Carver1  \n| \u003Cbr>ABSTRACT |  |\n| --- | --- |\n| Methionine aminopeptidase type 2 (METAP2) is a ubiquitous, evolutionarily conserved metalloprotease fundamental to protein biosynthesis which catalyzes removal of the N-terminal methionine residue from nascent polypeptides. METAP2 is an attractive target for cancer therapeutics based upon its over-expression in multiple human cancers, the importance of METAP2-speciﬁc substrates whose biological activity may be altered following METAP2 inhibition, and additionally, that METAP2 was identiﬁed as the target for the anti-angiogenic natural product, fumagillin. Irreversible inhibition of METAP2 using fumagillin analogues has established the anti-angiogenic and anti-tumor characteristics of these derivatives; however, their full clinical potential has not been realized due to a combination of poor drug-like properties and dose-limiting central nervous system (CNS) toxicity. This report describes the physicochemical and pharmacological characterization of SDX- 7320 (evexomostat), a polymer–drug conjugate of the novel METAP2 inhibitor (METAP2i) SDX-7539 . In vitro binding, enzyme, and cell-based assays demonstrated that SDX-7539 is a potent and selective METAP2 inhibitor. In utilizing a high molecular weight, water-soluble polymer to conjugate the novel fumagillol-derived, cathepsin-released, METAP2i SDX-7539, limitations observed with prior generation, small molecule fumagillol derivatives were ameliorated including reduced CNS exposure of the METAP2i, and prolonged half-life enabling convenient administration. Multiple xenograft and syngeneic cancer models were\u003Cbr>Introduction\u003Cbr>The cytoplasmic metalloproteases methionine aminopeptidase types 1 and 2 (METAP1 and METAP2) are fundamental in cellular function across prokaryotes and eukaryotes, primarily responsible for N-terminal methionine cleavage of proteins during de novo biosynthesis (1) . A limited number of METAP2-selective substrates have\u003Cbr>1SynDevRx, Inc., Cambridge, Massachusetts. 2Emerald BioVentures, New York, New York.\u003Cbr>Current address for J.S. Petersen: Glyscend Therapeutics, Lowell, Massachusetts; and current address for D.J. Turnquist, Hemavant Sciences, New York, New York.\u003Cbr>Corresponding Author: Peter Cornelius, SynDevRx, Inc., 1 Broadway, Fl 14,\u003Cbr>Cambridge, MA 02142 . E-mail: [pcornelius@syndevrx.com](pcornelius@syndevrx.com)\u003Cbr>[Mol Cancer Ther 2024](Mol Cancer Ther 2024);[23:595](23:595)–[605](605)\u003Cbr>[doi:](doi: 10.1158/1535-7163.MCT-23-0574)[ 10.1158/1535-7163.MCT-23-0574](doi: 10.1158/1535-7163.MCT-23-0574)\u003Cbr>This open access article is distributed under the Creative Commons AttributionNonCommercial-NoDerivatives 4 . 0 International (CC BY-NC-ND 4 . 0) license.\u003Cbr>􀀂2024The Authors;Published by the American Association for Cancer Research | utilized to demonstrate the anti-tumor and anti-metastatic proﬁle of SDX-7320 . Unlike polymer–drug conjugates in general, reductions in small molecule–equivalent efﬁcacious doses following polymer conjugation were observed. SDX-7320 has completed a phase I clinical safety study in patients with late-stage cancer and is currently being evaluated in multiple phase Ib/II clinical studies inpatients with advanced solid tumors.\u003Cbr>\u003Cbr>been reported to date: thioredoxin-1, cyclophilin A, eukaryotic elongation factor 2, RAB37, GAPDH, 14–3-3g and SH3 binding glutamic acid rich-like protein (2–4) . Inhibiting the aminopeptidase activity of METAP2 causes these substrates to retain their initiator methionine, thereby affecting post-translational modiﬁcations, protein folding, cellular localization, and stabilization (2, 3, 5, 6) .\u003Cbr>Fumagillin is a natural ","cbCaikSB7hDK7Z90","https://ap.wps.com/l/cbCaikSB7hDK7Z90","pdf",5176879,11,"English","# Abstract\n## Background and rationale for METAP2 targeting\n## Fumagillin and METAP2 biology\n## Limitations of prior inhibitors\n## SDX-7320/evexomostat approach and study design","[{\"question\":\"What biological role does METAP2 play that makes it relevant to cancer therapy?\",\"answer\":\"METAP2 is a metalloprotease that removes the N-terminal methionine from nascent polypeptides. Its inhibition can alter post-translational modifications, protein folding, localization, and stabilization, contributing to anti-tumor effects.\"},{\"question\":\"Why are fumagillin-based METAP2 inhibitors of interest, and what limitations exist?\",\"answer\":\"Fumagillin irreversibly binds selectively to METAP2 and inactivates its aminopeptidase activity, leading to downstream anti-tumor and anti-metastatic effects. Prior derivatives such as TNP-470 showed dose-limiting neurological toxicity and other pharmacokinetic or solubility challenges.\"},{\"question\":\"How does SDX-7320 (evexomostat) differ from earlier small-molecule approaches?\",\"answer\":\"SDX-7320 is a polymer–drug conjugate of the METAP2 inhibitor SDX-7539 designed to improve properties limited in earlier generations. The high molecular weight polymer conjugation reduces CNS exposure, prolongs half-life, and enables convenient administration.\"}]","Pharmacological Characterization of SDX-7320/Evexomostat - A Novel Methionine Aminopeptidase Type 2 Inhibitor with Anti-tumor and Anti-metastatic Activity | PDF",1790040593,28,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b996fd198ae68411e6ae3ebcc537393a.webp",983,1286,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2f5be6676e96fd3a2f73ebfce5d057ed.webp",982,1285,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/46ebfe4552cc67342bf78e946280b564.webp",981,1283,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b9586d41a2c7f28d408d327e3e926262.webp",980,1282]